The collaboration will focus on researching the prevalence of ALT in cancer and its genetic drivers to develop new treatments.

The collaboration will focus on researching the prevalence of ALT in cancer and its genetic drivers to develop new treatments.

The firm is focusing on hematology, immunology, and oncology, liver, and lung conditions, while seeking partnerships beyond these core areas.

The companies will initially develop an AI-based test to select patients with CDH17-expressing gastrointestinal cancers for Arbele's Phase I drug trial.

Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to ...

In a report, a working group cautioned that the program must lessen its reliance on congressional appropriations or risk ...

Researchers hope DeepGEM can expedite targeted treatment for lung cancer patients who can't access standard genomic testing.

NEW YORK – A majority of experts in the US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) voted on Thursday that the available data did not support the first-line use of ...

The Florida-based provider will work with AI software company AiraMed to analyze and measure patients' brain volume from MRIs.

Researchers at the ESMO Congress presented data showing better responses on dual-checkpoint blockade in the biomarker-defined ...

Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, ...